-
June 18, 2012
Recently, Bristol-Myers Squibb Company (BMY) and partner Otsuka Pharmaceutical Europe Ltd. presented six-year ...
-
June 11, 2012
Recently, Bristol-Myers Squibb (BMY) and partner AstraZeneca (AZN) presented encouraging data from a phase III study ...
-
June 06, 2012
Bristol-Myers Squibb Company (BMY) recently presented encouraging data from a late-stage study (AMPLE: n=646), which ...
-
June 05, 2012
As the world continues to modernize and grow, global cancer incidences are expected to increase exponentially and ...
-
May 04, 2012
Merck investors are getting paid to wait until top-line trends improve.
-
May 03, 2012
The pharmaceutical giant reported decent first quarter results late in April 2012. However, It will likely be some ...
-
April 25, 2012
A possible sale of Amylin might not be such a bad thing.
-
April 04, 2012
These three big drug stocks offer attractive yields and relative safety heading into the more challenging summer ...
-
March 21, 2012
Despite all of these uncertainties, investors still heavily focus on whether a company's new drug will be approved ...
-
February 06, 2012
Pfizer remains very profitable and has ample cushion to adjust its cost structure to maintain a respectable level of ...
-
January 30, 2012
Some of the biggest and highest-yielding drug stocks are declining near attractive buy levels, giving ...
-
January 27, 2012
Record corporate profits and super low interest rates are resulting in a shrinking market environment and a rise in ...
-
January 24, 2012
Here are four of the most attractive stocks based on fundamentals and the charts.
-
January 09, 2012
Bristol-Myers recently bought Inhibitex, a company leading the way in developing a treatment for Hepatitis C.
-
December 29, 2011
2011 was a surprisingly healthy year for drug stocks.
-
November 22, 2011
Gilead is going all in on Hep C, as it acquires Pharmasset in a massive deal.
-
September 30, 2011
Learn more about three large pharmaceutical companies with the highest current yields.
-
September 13, 2011
Caliper's rebound comes to an end with a premium take-out by PerkinElmer.
-
August 17, 2011
In the wake of big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors.
-
August 02, 2011
Selecting from the top dividend stocks owned by professional investors may give your portfolio a boost.
